Cargando…
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142107/ https://www.ncbi.nlm.nih.gov/pubmed/29775121 http://dx.doi.org/10.1177/1534735418775819 |
_version_ | 1783355808278380544 |
---|---|
author | Sun, Lingling Fahey, Paul Zhu, Xiaoshu Ng, Weng Chen, Zhuo Ping Qiu, Yiwen Lai, Hezheng Lin, Jietao Lin, Lizhu |
author_facet | Sun, Lingling Fahey, Paul Zhu, Xiaoshu Ng, Weng Chen, Zhuo Ping Qiu, Yiwen Lai, Hezheng Lin, Jietao Lin, Lizhu |
author_sort | Sun, Lingling |
collection | PubMed |
description | Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups (P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement. |
format | Online Article Text |
id | pubmed-6142107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61421072018-09-20 A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China Sun, Lingling Fahey, Paul Zhu, Xiaoshu Ng, Weng Chen, Zhuo Ping Qiu, Yiwen Lai, Hezheng Lin, Jietao Lin, Lizhu Integr Cancer Ther Research Articles Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups (P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement. SAGE Publications 2018-05-18 /pmc/articles/PMC6142107/ /pubmed/29775121 http://dx.doi.org/10.1177/1534735418775819 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Articles Sun, Lingling Fahey, Paul Zhu, Xiaoshu Ng, Weng Chen, Zhuo Ping Qiu, Yiwen Lai, Hezheng Lin, Jietao Lin, Lizhu A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title | A Cohort Study to Examine the Use of Chinese Herbal Medicine in
Combination With Conventional Therapies for Patients With Hepatocellular
Carcinoma in China |
title_full | A Cohort Study to Examine the Use of Chinese Herbal Medicine in
Combination With Conventional Therapies for Patients With Hepatocellular
Carcinoma in China |
title_fullStr | A Cohort Study to Examine the Use of Chinese Herbal Medicine in
Combination With Conventional Therapies for Patients With Hepatocellular
Carcinoma in China |
title_full_unstemmed | A Cohort Study to Examine the Use of Chinese Herbal Medicine in
Combination With Conventional Therapies for Patients With Hepatocellular
Carcinoma in China |
title_short | A Cohort Study to Examine the Use of Chinese Herbal Medicine in
Combination With Conventional Therapies for Patients With Hepatocellular
Carcinoma in China |
title_sort | cohort study to examine the use of chinese herbal medicine in
combination with conventional therapies for patients with hepatocellular
carcinoma in china |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142107/ https://www.ncbi.nlm.nih.gov/pubmed/29775121 http://dx.doi.org/10.1177/1534735418775819 |
work_keys_str_mv | AT sunlingling acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT faheypaul acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT zhuxiaoshu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT ngweng acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT chenzhuoping acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT qiuyiwen acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT laihezheng acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT linjietao acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT linlizhu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT sunlingling cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT faheypaul cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT zhuxiaoshu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT ngweng cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT chenzhuoping cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT qiuyiwen cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT laihezheng cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT linjietao cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT linlizhu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina |